Medtronic has made an offer for smaller medical device maker Intersect. Credit: Tony Webster.

Medtronic has received clearance for its LINQ II insertable cardiac monitor (ICM) from the Food and Drug Administration (FDA) in the US, as well as CE Mark in Europe.

LINQ II is a small, wireless ICM for patients with abnormal heart rhythms. These patients require long-term monitoring or continuous management as they experience dizziness, palpitations, syncope (fainting) and chest pain.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The system simplifies diagnosis and monitoring of the patients by providing enhanced accuracy to correctly detect abnormal heart rhythms.

It also eliminates the need for patients to return to the hospital by enabling clinicians to optimise its settings. It is designed to deliver improved device longevity compared to other ICMs.

Medtronic’s Cardiac and Vascular Group cardiac rhythm and heart failure division chief medical officer Rob Kowal said: “In the current Covid-19 environment, the LINQ II system offers patients a seamless way to experience ongoing connectivity between their device and their physician while reducing the need for in-office visits.

“LINQ II gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation (AF) or other abnormal heart rhythms.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic is planning to launch the LINQ IIICM in the US and Europe later this year.

Meanwhile, the company has made an offer for smaller medical device maker Intersect.

California-based Intersect specialises in drug-delivery tools for ear, nose and throat clinicians, treating chronic sinusitis.

According to a report by Bloomberg, Intersect’s board of directors is currently reviewing the offer with its advisers.